医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Sosei Acquires Jitsubo, a Leading Japanese Peptide Technology Company

2014年12月12日 PM01:51
このエントリーをはてなブックマークに追加


 

TOKYO

Sosei Group Corporation (“The Group”)(TOKYO:4565) is pleased to announce that at the meeting of the Board of Directors held today, it resolved to acquire existing shares and underwrite a third party allocation of new shares of Jitsubo Co., Ltd. (“Jitsubo”). Upon completion of these transactions, Jitsubo will become a consolidated subsidiary of the Group.

1. Reasons for the acquisition
The Group has successfully secured a steady revenue stream from milestones and royalty payments from COPD products licensed to Novartis (Seebri® Breezhaler® and Ultibro® Breezhaler®)*. However, in order to further enhance its corporate value, the Group has been looking for new pipeline candidates that could augment the revenue inflow from the two marketed Novartis products.

As a result, the Group has identified and resolved to acquire Jitsubo, a company with a cutting-edge peptide technology. Together with APNT (the nanoparticle technology of the Group’s subsidiary, Activus Pharma), Jitsubo’s technology is expected to play an important role in achieving the mid-long term strategic goals of the Group.

Jitsubo was established in April 2005 by Professor Kazuhiro Chiba of the United Graduate School of Agricultural Science, Tokyo University of Agriculture and Technology, with the aim of bringing a commercial focus to his scientific findings. The company is focused on development of peptide generic products and identification of new drug candidates based on the novel peptide synthesis technology, Molecular HivingTM 1, and the molecule modification technology, PeptuneTM 2. Together, these technologies enable efficient synthesis and isolation of peptide analogue compounds.

Expected benefits of the acquisition:

  • Acquiring a new platform technology will enable the Group to enter the peptide market
    Considerable expectation is placed on peptides as the next generation of drugs, as their smaller molecular weight compared to proteins facilitates organic synthesis. Additionally, due to higher mass and molecular diversity of peptides compared with small molecular weight compounds, it is anticipated that they may enable access to therapeutic targets that are difficult to control with small molecule treatments. There are currently over 50 marketed peptide products, and the peptide market is expected to reach $23 billion by 2020. Through the acquisition of Jitsubo the Group acquires a state-of-the-art technology that has a potential to become a generator of future revenue and growth.
  • Replenishing the existing pipeline with new peptide products will further enhance corporate value
    The two Jitsubo peptide generic products, as well as other drug candidates that are expected to follow in the future, will help replenish the Group’s existing pipeline and further enhance corporate value.
 
Development code   Indication   Development stage
JIT-2001 Cardio vascular diseases Pre-clinical
JIT-1007   Orphan diseases   Basic research
 

2. Share transaction
Based on the Investment agreement signed with Jitsubo, the Group will underwrite a third-party allocation for 68,871 new “Class D” shares that are to be issued by Jitsubo on 26 December. In addition, The Group will acquire 69,490 of the issued outstanding shares from the existing shareholders. As a result, the Group will own 52.4% of Jitsubo issued shares, making Jitsubo a consolidated subsidiary.

As 1 outstanding share holds 1 voting right, and 1 “Class D” share holds 3 voting rights, Sosei will hold 276, 103 voting rights of the total of 401,632. This equals to 68.7% of voting rights holding ratio.

 

3.  Overview of Jitsubo

1)   Company Name   Jitsubo Co., Ltd
2)   Address 2-24-16 Naka-cho, Koganei-shi, Tokyo
3)   Representative’s name and title Yusuke KOHNO, Executive Director CEO
4)   Business description Development of peptide drugs, licensing of peptide API manufacturing technology, research related to discovery of peptide drug candidates
5)   Capital 10 million yen
6)   Founded April 8, 2005
7)   Major shareholders

MSIVC CAMPUS NO.3 VENTURE CAPITAL INVESTMENT, L.P. : 18.3%
JMSEED BIO INCUBATION NO.1 VENTURE CAPITAL INVESTMENT, L.P. :10.9%
9 individual shareholders:70.8%

8)

 

Conflict of interest

Capital   None
Personnel None
  Transactions None

9)

  Jitsubo’s earnings results and financial position for the past three financial years
Financial Year FY2011   FY2012   FY2013
(Million Yen)
  Net assets (46) (94) (58)
  Total assets 22 19 40
(Yen)
  Net assets per share – diluted (532.87) (1,091.35) (429.23)
(Million Yen)
  Revenue 23 20 24
  Operating income/(loss) (60) (62) (40)
  Ordinary income /(loss) (34) (48) (38)
  Net income /(loss) (34) (48) (38)
(Yen)
  Net income per share – diluted (396.99) (558.48) (388.08)
  Dividends per share      
 

4. Existing shareholders from whom the shares will be acquired
The Group has reached agreement with 8 individual shareholders whose names and addresses were being withheld, as per their request for privacy. There are no conflicts of interest in terms of capital, personnel and business transactions that require disclosure.

 

5. Number of shares to be acquired, acquisition price and state of share ownership before and after acquisition

1)  

Number of shares held before transfer

  0 shares  
(Number of voting rights: 0)
  (Voting rights holding ratio: 0)      
2)

Number of shares to be acquired

Shares to be acquired from existing shareholders:

69,490 shares

Shares to be acquired through
third-party allocation of new shares:

68,871 shares (Class D)

 

(Number of voting rights: 206,613)

     
3) Acquisition price (Million Yen)

Acquisition of existing shares: 

211

Acquisition of new shares through

 

210

third-party allocation:

Advisory Expenses (Quote)

 

10

 

Total

 

431

 
4)

Number of shares held after transfer

138,361 shares
(Number of voting rights: 276,103)
    (Voting rights holding ratio: 68.7%)      
 

6.  Schedule

1)   Resolution date of the Board of Directors meeting   December 11, 2014
2)   Signing of the agreement: December 11, 2014
3)   Closing of transaction   December 26, 2014
 

7. Future prospects
The potential impact of the acquisition on future earnings is difficult to estimate at present. The Group will inform investors of any important matter arising from the transaction, in a timely and appropriate manner.

 

Forecast for the FY2014 (1 April 2014 to 31 March 2015) and actual results for FY2013

(Million Yen)

    Revenue  

Operating
income

 

Net income
before income
taxes

 

Net income

 

Net income attributable
to owners of the parent
company

FY2014 (E) 3,300 2,000 2,000 2,000
FY2013   2,069   756   737   1,526   1,526
 

* Seebri®, Ultibro® and Breezhaler® are registered trademarks of Novartis AG.

References:
1 Molecular Hiving™: Molecular HivingTM technology is Jitsubo’s patented technology for a novel liquid-phase peptide synthesis. Currently, two types of peptide synthesis technologies are widely used: solid-phase peptide synthesis (SPPS) and liquid-phase peptide synthesis (LPPS). SPPS is a high cost technology often applied for the small scale manufacturing, whereas LPPS is often applied for larger scale manufacturing, but cannot be used for long-chain peptide synthesis. Molecular HivingTM technology combines the benefits of both SPPS and LPPS, and provides the solution for efficient peptide synthesis at low costs. Moreover, since the monitoring of peptide synthesis process that was not possible with SPPS was enabled with this technology, high-quality peptide can be manufactured more easily than with the currently existing methods.
For more details please visit www.jitsubo.com.

2 Peptune™: PeptuneTM is a novel technology that enables arbitrary alteration of molecular configuration, without changing the amino acid sequence within the peptide. Compared to the existing similar technologies, it has a high structural diversity, which makes possible for pharmacological function and stability to be improved based on the molecular configuration of peptide. In addition, introducing a new functional molecule to a cross-linkage is also possible, and this new scientific approach enables the production of novel functional peptide.
For more details please visit www.jitsubo.com.

CONTACT

Sosei Group Corporation
Tokyo Office
Milica STOJKOVIC,
+81-(0)3-5210-3399
Investor Relations
mstojkovic@sosei.com
or
London
Office
Kathryn LYDON, +44-(0)20-7691-0983
PA to CEO &
Corporate Communication
klydon@sosei.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-402の第I相中間データを発表
  • Vedanta Biosciences Granted Four New U.S. Patents Expanding Coverage for Compositions and Methods of Use for Therapeutics Based on Microbiome-Derived Bacterial Consortia
  • Daiichi Sankyo and Puma Biotechnology Announce Research Collaboration with Major Cancer Center in HER2-Mutated Cancer
  • 武田和Seattle Genetics呈报3期ECHELON-1临床试验的阳性数据,该试验评估ADCETRIS® (brentuximab vedotin)用于晚期霍奇金淋巴瘤的一线治疗
  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-301の第I相中間データを発表